The OncoTrace test by RGCC is a versatile diagnostic tool designed to detect and monitor cancer through the presence of circulating tumor cells (CTCs) in the bloodstream. It serves as both a baseline assessment and a follow-up tool to evaluate the effectiveness of treatment protocols and detect potential recurrence after successful treatment. Here's how it works:

Blood Sample Collection

A blood sample is drawn from the patient, offering a simple, non-invasive way to gather critical diagnostic information.

Detection of Circulating Tumor Cells (CTCs)

The test identifies the presence and quantity of circulating tumor cells (CTCs) in the blood. These cells are released into the bloodstream by tumors and provide a reliable indicator of cancer activity.

Phenotype Marker Identification

The OncoTrace test detects phenotype markers associated with the tissue origin of the cancer, helping determine where the cancer is likely originating. This insight is especially valuable when the primary tumor site is unclear.

Stemness Marker Analysis

The test also evaluates stemness markers, which indicate the activity level and behavior of the CTCs. This information helps assess the cancer’s potential for:

• Aggressiveness (how rapidly it may grow).
• Metastasis (likelihood of spreading).
• Treatment resistance (how well it may respond to therapy).
• Recurrence (risk of the cancer returning after treatment).

Comprehensive Cancer Detection

The OncoTrace test detects all cancer types, including hematologic (blood) and solid tumors, except for those originating in the central nervous system (CNS). This broad applicability makes it a powerful tool for cancer management.

Monitoring and Prognosis

The test is used throughout the cancer care journey to:

• Establish a baseline: Evaluate the initial presence and activity of cancer.
• Monitor treatment effectiveness: Track changes in CTC levels to assess whether therapies are working.
• Detect recurrence early: Provide long-term monitoring after successful treatment to identify cancer recurrence before symptoms appear.

Key Benefits of the OncoTrace Test

1. Non-Invasive: Requires only a simple blood draw, eliminating the need for invasive biopsies.
2. Early Detection of Cancer Activity: Identifies cancer presence and activity before traditional imaging or other methods.
3. Broad Applicability: Detects a wide range of cancers, including hematologic and solid tumors.
4. Personalized Insights: Identifies phenotype and stemness markers to guide treatment decisions and assess prognosis.
5. Long-Term Monitoring: Tracks progress and recurrence risks over time, providing peace of mind and enabling timely intervention.

The OncoTrace test is a cornerstone of personalized cancer care, offering precise, actionable insights to guide treatment and improve outcomes. By detecting and monitoring cancer at a cellular level, it empowers patients and practitioners to make informed, proactive decisions throughout the care journey.